Patient-Reported Outcome in Metastatic Breast Cancer and Platinum-Resistant Recurrent Ovarian Cancer Patients Treated with Metronomic Cyclophosphamide ± Methotrexate: PROmetronomic.

[INTRODUCTION] Maintenance of subjective well-being and health-related quality of life (HRQoL) play a crucial role in the treatment of metastatic cancer. The metronomic chemotherapy (MCT) may be a favorable treatment option in metastatic breast cancer (MBC) and platinum-resistant recurrent ovarian cancer (ROC). The aim of this study was to evaluate the HRQoL of MBC and ROC patients treated with MCT.

[METHODS] PROmetronomic was a prospective, monocentric study evaluating the HRQoL in MBC and ROC patients treated with oral cyclophosphamide 50 mg daily (+ oral methotrexate 2.5 mg every other day for MBC) from August 2020 to August 2022. The data were obtained using EORTC QLQ-C30, BR23, OV28, and HADS-D via the eHealth-based platform CANKADO. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.

[RESULTS] A total of 5 MBC patients and 9 ROC patients were evaluated. The mean global health status was 47.2 at baseline and 36.1 at the end of MCT (p = 0.350). Functional scales and symptoms remained stable during MCT except for the significant increase of fatigue (51.9 vs. 77.8, p = 0.038). Anxiety and depression were without significant alteration (9.1 and 8.1 at baseline vs. 9.3 and 8.1 after MCT). The median PFS and OS were 10.0 weeks and 28.0 weeks, respectively. No ≥grade 3 toxicities were reported.

[CONCLUSION] MCT had no significant impact on HRQoL of our small cohort of heavily pretreated MBC and ROC patients and may represent a valuable treatment option for maintaining HRQoL in selected patients.